Scarica l'app Stockscreener
6.13
3.20%
0.19
Pre-mercato:
6.12
-0.010
-0.16%
Gyre Therapeutics Inc Borsa (GYRE) Ultime notizie
Gyre Therapeutics Inc (GYRE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Gyre Therapeutics Inc (GYRE) Balance Sheet - TradingKey
Gyre Therapeutics Inc (GYRE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Gyre Therapeutics Inc (GYRE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Gyre Therapeutics Inc (GYRE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GYRE|Gyre Therapeutics Inc|Price:6.110|Chg%:+0.170 - TradingKey
Gyre Therapeutics Inc (GYRE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Gyre Therapeutics Inc (GYRE) Income Statement - TradingKey
Gyre Therapeutics Inc (GYRE) Cash Flow - TradingKey
Cash flow from financing activities of Gyre Therapeutics Inc – GETTEX:L9S - TradingView
Gyre Therapeutics, Inc. Revenue Breakdown – NASDAQ:GYRE - TradingView
Gyre Therapeutics Inc (GYRE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Return on assets % of Gyre Therapeutics Inc – MUN:L9S - TradingView
Discontinued operations of Gyre Therapeutics Inc – MUN:L9S - TradingView
Return on assets % of Gyre Therapeutics Inc – GETTEX:A3EE5F - TradingView
Gyre Therapeutics Inc Statistics – MUN:L9S - TradingView
Gyre Therapeutics Inc Statistics – GETTEX:A3EE5F - TradingView
Gyre Therapeutics, Inc. (L9S.F) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Gyre Therapeutics Strengthens Board with New Director Appointments - The Globe and Mail
Gyre Therapeutics appoints three directors to board By Investing.com - Investing.com Nigeria
Gyre Therapeutics appoints three directors to board - Investing.com
Gyre Therapeutics (Nasdaq: GYRE) adds three directors, expanding expertise - Stock Titan
Gyre Therapeutics Appoints Three New Members to its Board of Directors - The Manila Times
Gyre Therapeutics, Inc. Announces Board and Committee Changes, Effective August 1, 2026 - marketscreener.com
Gyre Therapeutics Inc. (GYRE) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Surprise in Pre-Revenue StageNew Analyst Coverage - dars.gov.et
Gyre Therapeutics (GYRE) Registration filing Summary - Quartr
Gyre Adds Director With Drug Development Experience Across China, Japan - Stock Titan
Cullgen $300M all-stock deal expands Gyre Therapeutics (Nasdaq: GYRE) - Stock Titan
Yue Xiong Net Worth (2026) - GuruFocus
Jialiang (nmn) Wang Net Worth (2026) - GuruFocus
Joshua Benjamin Bergmann Net Worth (2026) - GuruFocus
Form S-3/A Gyre Therapeutics Inc For: 13 July By Investing.com - Investing.com Nigeria
Gyre Therapeutics (Nasdaq: GYRE) details 31.3M-share resale and China risks - Stock Titan
GYRE Q1 2026 Earnings: Narrower-than-expected loss as EPS beats estimates; stock slipsEarnings Surprise Report - DonanımHaber
Gyre Therapeutics Q1 2026 Earnings: EPS Beats Estimates Despite Revenue Absence; Stock DeclinesReturn On Capital - DonanımHaber
Gyre Therapeutics highlights pipeline progress as investors watch fibrosis focus - ad-hoc-news.de
GYREGyre Therapeutics Inc Options - Finviz
Form 4 Gyre Therapeutics Inc For: 30 June By Investing.com - Investing.com Nigeria
Gyre Therapeutics (GYRE) director awarded 40,000 stock options at $5.95 - Stock Titan
Director Dan Weng receives 40,000-share option grant at GYRE (NASDAQ: GYRE) - Stock Titan
GYRE SEC FilingsGyre Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
US High Growth Tech Stocks to Watch - simplywall.st
Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Value Benchmark - marketscreener.com
GYRE THERAPEUTICS (GYRE): Kaskela Law LLC Announces Shareholder Investigation of Gyre Therapeutics and Encourages Long-Term GYRE Investors to Contact the Firm - ACCESS Newswire
Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Value-Defensive Index - marketscreener.com
Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Growth-Defensive Index - marketscreener.com
Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Defensive Index - marketscreener.com
Price to earnings forward of Gyre Therapeutics, Inc. – NASDAQ:GYRE - TradingView
Price to earnings forward of Gyre Therapeutics Inc – LS:A3EE5F - TradingView
Price to book forward of Gyre Therapeutics, Inc. – NASDAQ:GYRE - TradingView
Enterprise value to EBITDA forward of Gyre Therapeutics, Inc. – NASDAQ:GYRE - TradingView
Enterprise value to EBIT forward of Gyre Therapeutics Inc – TRADEGATE:L9S - TradingView
Price to earnings forward of Gyre Therapeutics Inc – TRADEGATE:L9S - TradingView
Gyre Therapeutics Inc (GYRE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Gyre Therapeutics Inc Actuals & Estimates (NASDAQ:GYRE) - TradingView
Enterprise value to revenue forward of Gyre Therapeutics, Inc. – NASDAQ:GYRE - TradingView
Price to book forward of Gyre Therapeutics Inc – LS:A3EE5F - TradingView
GYRE Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBIT forward of Gyre Therapeutics, Inc. – NASDAQ:GYRE - TradingView
Price to sales forward of Gyre Therapeutics, Inc. – NASDAQ:GYRE - TradingView
Price to sales forward of Gyre Therapeutics Inc – LS:A3EE5F - TradingView
GNI’s Gyre Therapeutics files Form S-3 tied to Cullgen acquisition - TipRanks
Gyre Therapeutics | S-3: Registration statement for specified transactions by certain issuers - Moomoo
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):